Mostrar el registro sencillo del ítem
dc.contributor.author | García de la Sota, Patricia | |
dc.contributor.author | Lorente, Elena | |
dc.contributor.author | Notario, Laura | |
dc.contributor.author | Mir-Gerrero, Carmen | |
dc.contributor.author | Zaragoza, Oscar | |
dc.contributor.author | Lopez, Daniel | |
dc.date.accessioned | 2022-05-03T09:48:19Z | |
dc.date.available | 2022-05-03T09:48:19Z | |
dc.date.issued | 2021-09-07 | |
dc.identifier.citation | Biomedicines. 2021;9(9):1176. | es_ES |
dc.identifier.issn | 2227-9059 | es_ES |
dc.identifier.uri | http://hdl.handle.net/20.500.12105/14234 | |
dc.description.abstract | Human respiratory syncytial virus (HRSV) is the most common cause of severe respiratory infections in infants and young children, often leading to hospitalization. In addition, this virus poses a serious health risk in immunocompromised individuals and the elderly. HRSV is also a major nosocomial hazard in healthcare service units for patients of all ages. Therefore, the development of antiviral treatments against HRSV is a global health priority. In this study, mitoxantrone, a synthetic anthraquinone with previously reported in vitro antiprotozoal and antiviral activities, inhibits HRSV replication in vitro, but not in vivo in a mice model. These results have implications for preclinical studies of some drug candidates. | es_ES |
dc.description.sponsorship | This work was supported by the Spanish Ministry of Science and Innovation SAF2014-58052 and “Acción Estratégica en Salud” MPY 388/18 to D.L. | es_ES |
dc.language.iso | eng | es_ES |
dc.publisher | Multidisciplinary Digital Publishing Institute (MDPI) | es_ES |
dc.type.hasVersion | VoR | es_ES |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ | * |
dc.subject | HRSV | es_ES |
dc.subject | Antivirals | es_ES |
dc.subject | Bioluminescence | es_ES |
dc.subject | Drugs | es_ES |
dc.title | Mitoxantrone Shows In Vitro, but Not In Vivo Antiviral Activity against Human Respiratory Syncytial Virus | es_ES |
dc.type | journal article | es_ES |
dc.rights.license | Atribución 4.0 Internacional | * |
dc.identifier.pubmedID | 34572362 | es_ES |
dc.format.volume | 9 | es_ES |
dc.format.number | 9 | es_ES |
dc.format.page | 1176 | es_ES |
dc.identifier.doi | 10.3390/biomedicines9091176 | es_ES |
dc.contributor.funder | Ministerio de Ciencia e Innovación (España) | es_ES |
dc.contributor.funder | Instituto de Salud Carlos III | es_ES |
dc.description.peerreviewed | Sí | es_ES |
dc.relation.publisherversion | https://doi.org/10.3390/biomedicines9091176 | es_ES |
dc.identifier.journal | Biomedicines | es_ES |
dc.repisalud.centro | ISCIII::Centro Nacional de Microbiología | es_ES |
dc.repisalud.institucion | ISCIII | es_ES |
dc.rights.accessRights | open access | es_ES |
dc.relation.projectFECYT | info:eu-repo/grantAgreement/MINECO//SAF2014-58052-R/ES/DISEÑO DE VACUNAS RECOMBINANTES POLIEPITOPICAS PARA GENERAR RESPUESTAS T CD8+ CONTRA VIRUS EMERGENTES/ | es_ES |
dc.relation.projectFIS | info:eu-repo/grantAgreement/ES/MPY388/18 | es_ES |